U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.30
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.80
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    109.58
    +1.15 (+1.06%)
     
  • Gold

    1,809.10
    +7.60 (+0.42%)
     
  • Silver

    19.77
    +0.11 (+0.55%)
     
  • EUR/USD

    1.0448
    +0.0022 (+0.21%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2143
    +0.0040 (+0.33%)
     
  • USD/JPY

    135.5220
    +0.3470 (+0.26%)
     
  • BTC-USD

    19,555.14
    +567.74 (+2.99%)
     
  • CMC Crypto 200

    423.84
    +3.70 (+0.88%)
     
  • FTSE 100

    7,249.03
    +80.38 (+1.12%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

UPDATE — Inspire Medical Systems, Inc. to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc.

MINNEAPOLIS, June 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at the Terranea Resort in Rancho Palos Verdes, CA.

Inspire is scheduled to present at 7:00 p.m. Eastern Time. The presentation will be accessible via a live webcast at https://kvgo.com/gs/inspire-medical-systems-inc-june-2022.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989